
Bioinvent AB licences BI-1206 to CASI Pharmaceuticals
Cancer antibody specialist BioInvent International AB has granted the exclusive rights to market its anti-FcγRIIB antibody, BI-1206, in China,...

Germany first EU country to launch COVID-19 therapy offensive?
"Besides protection by masks, social distancing etc, rapid diagnostic testing, and COVID-19 vaccines, we are now establishing a fourth pillar of...

EU approves second COVID-19 vaccine
The EU has secured a total of 160 million doses of mRNA-1273 from the US-American manufacturer Moderna, which has outsourced production sites on the...

LSP leads €21m round into Neurent Medical
Galway-based medical device company Neurent Medical, which is focussed on chronic inflammatory diseases of the sinuses and nasal passages said it...

ADC company Araris Biotech raises CHF15.2m
Besides Pureos Bioventures, London-based 4BIO Capital, btov Partners, Redalpine, VI Partners and Schroder Adveq cofinanced the CHF12.7m addition to...

German researchers find reason for remdesivir's inefficiency
“We have come to a simple conclusion,” said Max Planck Director Patrick Cramer at the MPI for Biophysical Chemistry. “Remdesivir does interfere with...

Drug set to rescue COVID-19 patients at ICUs
Initial data from an US expanded access (EA) use of RLF-100™ (aviptadil) in 90 ICU patients with critical COVID-19 and severe comorbidities...